Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

T-helper 1 and 2 cell densities, and mesenteric cytokine levels, are prognostic markers in colorectal cancer.

Journal of gastrointestinal oncology·2026
Same author

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells.

Circulation·2026
Same author

Author Correction: Plasma membrane curvature regulates the formation of contacts with the endoplasmic reticulum.

Nature cell biology·2026
Same author

Multimodal atlas of human atherosclerosis links granular vascular cell states to coronary artery disease risk.

medRxiv : the preprint server for health sciences·2026
Same author

When modifier genes shape arrhythmic risk: gene-dependent effects in long QT syndrome.

European heart journal·2026
Same author

Hypoxia Induces Adaptive Lymphangiogenesis via Cd74 and Vegfr3 to Modulate Pulmonary Hypertension.

Circulation research·2026

相关实验视频

Updated: Jun 8, 2026

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
10:38

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver

Published on: May 4, 2016

16.2K

将人类肠道器官物质集成到FDA的药物发现新方法方法中.

Debarun Patra1,2, Ibrahim M Sayed3, Souhrid Mukherjee3

  • 1Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 2, 2026
PubMed
概括

人类肠道器官 (HIO) 提供了比肠道疾病的动物模型更准确的临床前毒性测试方法. 这些先进的模型改善了药物安全性评估,减少了动物使用,与监管转变保持一致.

关键词:
美国食品和药物管理局的新方法方法论.发现药物的发现.胃肠道毒性 胃肠道毒性人类肠道有机体炎症性肠病是一种炎症性肠病.

相关实验视频

Last Updated: Jun 8, 2026

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
10:38

In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver

Published on: May 4, 2016

16.2K

科学领域:

  • 生物医学工程 生物医学工程
  • 药物发现 药物发现 药物发现
  • 毒理学 毒理学 毒理学

背景情况:

  • 传统的毒性测试依赖于动物模型,这些动物模型与人类有显著的生理和遗传差异,导致药物消耗率高.
  • 复杂的疾病如炎症性肠病 (IBD) 在临床试验中面临超过85%的消耗,这是由于临床前模型中的特定物种差异.
  • 像FDA这样的监管机构正在推动新方法方法 (NAMs) 来增强与人类相关的测试系统.

研究的目的:

  • 突出人类肠道有机体 (HIO) 的潜力,作为先进的,与人类相关的模型,用于临床前药物毒性测试.
  • 展示HIO如何在药物开发中弥合体外试验和临床结果之间的差距.
  • 支持FDA的NAM路线图,通过展示HIO来改善药物安全评估和减少动物模型依赖.

主要方法:

  • 利用复制人类肠道结构,功能和细胞多样性的人类肠道器官 (HIOs).
  • 在受控的体外环境中使用HIO研究药物吸收,代谢和毒性.
  • 在新兴的临床试验中利用患者衍生肠道器官 (PDO) 来验证临床前发现.

主要成果:

  • HIOs忠实地复制人类的肠道复杂性,使药物效应的准确研究成为可能.
  • HIOs有助于预测毒动力学和药动力学,提供比传统方法更可靠的评估.
  • 患者衍生有机体 (PDO) 在临床试验中显示出前景,证实了有机体技术的翻译潜力.

结论:

  • 人类肠道器官 (HIOs) 代表了在肠道疾病中进行临床前药物安全性评估的变革性工具.
  • HIO提供了一个与监管趋势保持一致的与人类相关的平台,并可以显著减少对动物模型的依赖.
  • 将HIO和PDO纳入药物开发管道有望提高预测准确性并降低临床试验退出率.